AbbVie settles RINVOQ patent litigation; no generic entry until at least April 2037

AbbVie Inc.

Settled litigation with all generic manufacturers over RINVOQ (upadacitinib) ANDAs.
No generic entry expected before April 2037 in the US, assuming pediatric exclusivity.
Extends AbbVie's market exclusivity for RINVOQ, a key immunology drug.
Settlement and license agreements subject to standard acceleration provisions.
Removes a significant overhang for AbbVie's revenue stream.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.